宿主代谢组预测CAR T细胞治疗所致急性毒性的严重程度与发生时间
本研究针对接受抗CD19 CAR T细胞治疗(阿基仑赛或替沙仑赛)的复发/难治性大B细胞淋巴瘤患者,采用非靶向代谢组学及靶向检测验证,发现治疗前宿主代谢物与临床显著细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)的风险及发生时间相关,提示治疗前代谢组具有生物标志物潜力。
要点
- 治疗前血浆葡萄糖较高、胆固醇和谷氨酸较低与CRS发生更快相关。
- 治疗前脯氨酸、甘氨酸及次级胆汁酸异熊去氧胆酸基线水平低与临床显著CRS显著相关。
- 治疗前羟脯氨酸较低与ICANS级别更高及发生更快相关,谷氨酰胺低与ICANS发生更快负相关。
核心结论
- 治疗前宿主代谢组具有判断临床显著CRS和ICANS风险的生物标志物潜力,可能有助于抗CD19 CAR T细胞治疗前的患者风险分层。
研究设计与样本
- 研究分析接受阿基仑赛或替沙仑赛治疗的患者治疗前宿主代谢物,采用非靶向代谢组学分析及靶向检测验证。
主要发现
- 非靶向代谢组学分析与靶向检测验证均显示,特定治疗前生化成分丰度与临床显著CRS(q<.1)和/或ICANS(q<.25)风险增加及/或发生相关。
- 治疗前血浆葡萄糖较高、胆固醇和谷氨酸较低与CRS发生更快相关。
- 治疗前脯氨酸、甘氨酸及次级胆汁酸异熊去氧胆酸基线水平低与临床显著CRS显著相关。
- 治疗前羟脯氨酸浓度较低与ICANS级别更高及发生更快相关,谷氨酰胺低与ICANS发生更快负相关。
关键数值与推荐
- 临床显著CRS的关联分析q<.1。
- ICANS的关联分析q<.25。
临床怎么用
- 原文结论指出治疗前宿主代谢组可能有助于抗CD19 CAR T细胞治疗前的患者风险分层,以辅助及时制定缓解策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a highly effective treatment option for patients with relapsed/refractory large B-cell lymphoma. However, widespread use is deterred by the development of clinically significant acute inflammatory toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), that induce significant morbidity and require close monitoring. Identification of host biochemical signatures that predict the severity and time-to-onset of CRS and ICANS may assist patient stratification to enable timely mitigation strategies. Here, we report pretreatment host metabolites that are associated with CRS and ICANS induced by axicabtagene ciloleucel or tisagenlecleucel therapy. Both untargeted metabolomics analysis and validation using targeted assays revealed a significant association between the abundance of specific pretreatment biochemical entities and an increased risk and/or onset of clinically significant CRS (q < .1) and ICANS (q < .25). Higher pretreatment levels of plasma glucose and lower levels of cholesterol and glutamate were associated with a faster onset of CRS. In contrast, low baseline levels of the amino acids proline and glycine and the secondary bile acid isoursodeoxycholate were significantly correlated with clinically significant CRS. Lower concentration of the amino acid hydroxyproline was associated with higher grade and faster onset of ICANS, whereas low glutamine was negatively correlated with faster development of ICANS. Overall, our data indicate that the pretreatment host metabolome has biomarker potential in determining the risk of clinically significant CRS and ICANS, and may be useful in risk stratification of patients before anti-CD19 CAR T-cell therapy.
引用
- Jalota A, Hershberger CE, Patel MS, et al. Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy. Blood Adv. 2023. PMID: 36399526. doi:10.1182/bloodadvances.2022007456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。